Johnnie L. Cochran, Jr., Brain Tumor Center
Cedars-Sinai Medical Center opened the Johnnie L. Cochran Brain Tumor Center on May 3, 2007 to shepherd basic research discoveries through patient trials and the government approval process. Learn More.
In the News
Are cell phones dangerous?
Johnnie Cochran's widow, Dale, and his neurosurgeon Dr. Keith Black, Chairman of the Cedars-Sinai Department of Neurosurgery, discuss how cell phones may have led to Johnnie Cochran's death. To listen to the interview, please click here.
Battling a Deadly Foe: Researchers at Cedars-Sinai are racing to develop experimental treatments, and even vaccines, for fast-growing malignant tumors like the one Senator Edward Kennedy has been diagnosed with. To read the entire Newsweek article, please click here.
Make a Donation
If you are interested in making a gift to the Johnnie L. Cochran, Jr Brain Tumor Center, please call (310) 423-3655 or toll-free (877) 427-2443 or email us at GroupCRGiftProcessing@cshs.org.
| Send Us a Message |
You may also download, print and complete the donation form and mail it to Cedars-Sinai Medical Center, P. O. Box 48750 - Tribute/Suite 2416, Los Angeles, California 90048-0750. 
For Brain Tumor Patients
The Department of Neurosurgery through the Malignant Tumor Program and the Benign Tumor Program treats the full range of tumors affecting the brain and central nervous system. The department also has a specialized, multidisciplinary team of experts dedicated to treating pediatric patients through the Pediatric Neurosurgery Program.
The department offers a full range of support and information for brain tumor patients, including:
- Your Surgery Guide and Resources
- Coping With Your Diagnosis
- Psychological Services
- Services for Patients and Visitors
Clinical Trials
As a research facility, we often invite our patients to participate in clinical trials of new drugs and other therapies. The following links describe some of the cutting-edge research studies and clinical trials we are currently directing or have completed. For more information, visit our Research and Outcomes section.
You will need the Adobe® Reader® to view and print the following document from your desktop. If you do not have this software, you can download it FREE from Adobe's website.
- Phase II Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients with Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System
- 131I-TM-601 for Recurrent High Grade Glioma
- Gliadel and Dendritic Cell Vaccine for Malignant Tumors
- Immunotherapy For Brain Stem Gliomas
- Immunotherapy and Temodar in the Treatment of Glioblastoma Multiforme
- Phase I Study of Gefitinib and Rapamycin in Patients with Recurrent or Progressive Glioblastoma Multiforme
- Phase 1 Study of Pioglitazone and Isotretinoin in Patients with Recurrent or Progressive Glioblastoma Multiforme
- Bevacizamab for Primary Brain Tumors
- Improving Quality of Life for Brain Tumor Patients
- New test for glial tumors: Laminin 411
For Windows Media Player, please click here.
For an appointment, a second opinion or more information, please call 1-800-CEDARS-1 (1-800-233-2771) or e-mail us.
